Improvement in physicochemical properties of ezetimibe using a crystal engineering technique

Powder Technology

Volumn 222, Issue , 2012, Pages 131-138

  Mulye, Snehal P ^a   Jamadar, Samina A ^a   Karekar, Poonam S ^a   Pore, Yogesh V ^a   Dhawale, Shashikant C ^a  

^a Government College of Pharmacy   (India)

Author keywords

Benzoic acid; Crystal engineering; Dissolution; Ezetimibe; Physicochemical properties; Salicylic acid

Indexed keywords

BENZOIC ACID; CO-CRYSTALS; CRYSTALLINITIES; DISSOLUTION PROFILES; DRUG CONTENT; ENGINEERING TECHNIQUES; EQUIMOLAR RATIO; EZETIMIBE; FLOW PROPERTIES; FLOWABILITY; FTIR; HYDROGEN BONDING INTERACTIONS; MORPHOLOGICAL CHARACTERISTIC; PHASE SOLUBILITY; PHYSICOCHEMICAL PROPERTY; SALICYLIC ACIDS; SATURATION SOLUBILITY; SCANNING ELECTRON MICROSCOPIES (SEM); SOLUTION CRYSTALLIZATION; X-RAY POWDER DIFFRACTOMETRY;

CARBOXYLIC ACIDS; CRYSTAL ENGINEERING; FOURIER ANALYSIS; FOURIER TRANSFORMS; HYDROGEN BONDS; INFRARED SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SOLUBILITY;

DISSOLUTION;

ACETIC ACID; BENZOIC ACID; EZETIMIBE; SALICYLIC ACID;

ARTICLE; CHEMICAL ENGINEERING; CHEMICAL INTERACTION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG PURITY; DRUG SOLUBILITY; DRUG STRUCTURE; FLOW KINETICS; HYDROGEN BOND; INFRARED SPECTROSCOPY; MELTING POINT; PARTICLE SIZE; PH MEASUREMENT; PHASE TRANSITION; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SURFACE PROPERTY; X RAY POWDER DIFFRACTION;

EID: 84858750959     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2012.02.020     Document Type: Article

References (51)

1. Paul E.L., Tung H.H., Midler M. Organic crystallization processes. Powder Technology 2005, 150:133-143.
2. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs 1999, SSCI, West Lafayette.
3. Polymorphism in pharmaceutical solids 1999, Vol. 95. Marcel Dekker, New York. H. Brittain (Ed.).
4. Llinas A., Goodman J.M. Polymorph control: past, present and future. Drug Discovery Today 2008, 13:198-210.
5. Yadav A.V., Shete A.S., Dabke A.P., Kulkarni P.V., Sakhare S.S. Co-crystals: a novel approach to modify physicochemical properties of active ingredients, Indian. Journal of Pharmaceutical Sciences 2009, 71:359-370.
6. Chaumeil J.C. Micronisation: a method of improving the bioavailability of poorly soluble drugs. Methods and Findings in Eperimental and Clinical Pharmacology 1998, 20:211-215.
7. Humberstone A.J., Charman W.N. Lipid-based vehicles for the oral delivery of poorly soluble drugs. Advanced Drug Delivery Reviews 1997, 25:103-128.
8. Agharkar S., Lindenbaum S., Higuchi T. Enhancement of solubility of drug salts by hydrophilic counter-ions: properties of organic salts of an anti-malarial drug. Journal of Pharmaceutical Sciences 1976, 65:747-749.
9. Schott H., Kwan L.C., Feldman S. The role of surfactant in the release of very slightly soluble drugs from tablets. Journal of Pharmaceutical Sciences 1982, 71:1038-1045.
10. Amin K., Dannenfelser R.M., Zielinski J., Wang B. Lyophilization of polyethylene glycol mixtures. Journal of Pharmaceutical Sciences 2004, 93:2244-2249.
11. Veiga F., Teixeria-Dias J.J.C., Kedzeierewicz F., Sousa A., Maincent P. Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. International Journal of Pharmaceutics 1996, 129:63-71.
12. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. Journal of Pharmaceutical Sciences 1971, 60:1281-1302.
13. Christian L., Dressman J. Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics 2000, 50:47-60.
14. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. Journal of Pharmaceutical Sciences 1999, 88:1058-1066.
15. Childs S.L., Chyall L.J., Dunlap J.T., Smolenskaya V.N., Stahly B.C., Stahly G.P. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic and fumaric acids. Journal of the American Chemical Society 2004, 126:13335-13342.
16. Remenar J.F., Morissette S.L., Peterson M.L., Moulton B., MacPhee J.M., Guzman H.R., Almarsson O. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. Journal of the American Chemical Society 2003, 125:8456-8457.
17. McNamara D.P., Childs S.L., Giordano J., Iarriccio A., Cassidy J., Shet M.S., Mannion R., O'Donnell E., Park A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharmaceutical Research 2006, 23:1888-1897.
18. Trask A.V., Motherwell W.D.S., Jones W. Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. Crystal Growth and Design 2005, 5:1013-1021.
19. Trask A.V., Motherwell W.D., Jones W. Physical stability enhancement of theophylline via cocrystallization. International Journal of Pharmaceutics 2006, 320:114-123.
20. Vishweshwar P., McMahon J.A., Bis J.A., Zaworotko M.J. Pharmaceutical co-crystals. Journal of Pharmaceutical Sciences 2006, 95:499-516.
21. Mirza S., Miroshnyk I., Heinamaki J., Yliruusi J. Co-crystals: an emerging approach for enhancing properties of pharmaceutical solids. Dosis 2008, 24:90-96.
22. Rodríguez-Hornedo N., Nehm S.J., Jayasankar A. Cocrystals: Design, Properties and Formation Mechanisms, in: Encyclopedia of Pharmaceutical Technology 2007, Taylor & Francis, London, 615-635. third ed.
23. Schultheiss N., Newman A. Pharmaceutical co-crystals and their physicochemical properties. Crystal Growth and Design 2009, 9:2950-2967.
24. Remenar J.F., Morissette S.L., Peterson M.L., Moulton B., MacPhee J.M., Guzman H., Almarsson O. Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. Journal of the American Chemical Society 2003, 125:8456-8457.
25. Almarsson O., Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?. Chemical Communications 2004, 17:1889-1896.
26. Sekhon B.S. Pharmaceutical co-crystals-a review. Ars Pharmaceutica 2009, 50:99-117.
27. Shiraki K., Takata N., Takano R., Hayashi Y., Terada K. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharmaceutical Research 2008, 25:2581-2592.
28. Woodlinger A.M. Cardiovascular drugs. Remington The Science and Practice of Pharmacy 2005, 1367. Lippincott Williams and Wilkins, Philadelphia. D.B. Troy (Ed.).
29. Zetia Drug Description RxList.com New York: The Internet Drug Index WebMD, Inc Available at, Accessed on November 25, 2010. http://www.rxlist.com/zetia-drug.htm.
30. Horter D., Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews 1997, 25:3-14.
31. Proudfoot S. Factors affecting bioavailability: factors influencing drug absorption from gastrointestinal tract. Pharmaceutics: The Science of Dosage Form Design 1991, 135-173. Churchil Livingstone, Edinburgh. M.E. Aulton (Ed.).
32. Patel R., Bhimani D., Patel J., Patel D. Solid-state characterization and dissolution properties of ezetimibe-cyclodextrins inclusion complexes. Journal of Inclusion Phenomena and Macrocyclic Chemistry 2008, 60:241-251.
33. Sancheti P.P., Karekar P., Vyas V.M., shah M., Pore Y.V. Preparation and physicochemical characterization of surfactant based solid dispersions of ezetimibe. Pharmazie 2009, 64:227-231.
34. Dixit R.P., Nagarsenker M.S. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. European Journal of Pharmaceutical Sciences 2008, 35:183-192.
35. Higuchi T., Connors K.A. Phase-solubility techniques. Advances in Analytical Chemistry and Instrumentation 1965, 4:117-212.
36. Nehm S.J., Rodríguez-Spong B., Rodríguez-Hornedo N. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Crystal Growth and Design 2006, 6(2):592-600.
37. Zhang G.G.Z., Henry R.F., Borchardt T.B., Lou X. Efficient cocrystal screening using solution-mediated phase transformation. Journal of Pharmaceutical Sciences 2007, 96:990-995.
38. Labhasetwar V., Deshmukh S.V., Dorle A.K. Studies on some crystalline forms of ibuprofen. Drug Development and Industrial Pharmacy 1993, 19:631-641.
39. Nokhodchi A., Maghsoodi M., Hassanzadeh D. An improvement of physicomechanical properties of carbamazepine crystals, Iranian. Journal of Pharmacy Research 2007, 6:83-93.
40. Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharmaceutical Research 1997, 14:556-567.
41. Childs S.L., Rodriguez-Hornedo N., Reddy L.S., Jayasankar A., Maheshwari C., McCausland L., Shipplett R., Stahly B.C. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Crystal Engineering Communications 2008, 10:856-864.
42. Subrahmanyam C.V.S. Micromeritics, Textbook of Physical Pharmaceutics 2000, 221-227. Vallabh Prakashan, Delhi. second ed.
43. Kawashima Y., Imai M., Takeuchi H., Yamamoto H., Kamiya K., Hino T. Improved flowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct tableting designed by spherical crystallization process. Powder Technology 2003, 130:283-289.
44. Sinko P.J. Micromeritics, Martins Physical Pharmacy and Pharmaceutical Sciences 2007, 557. Lippincott Williams and Wilkins. fifth ed.
45. Buckton G. Solid state properties. Pharmaceutics: The Science of Dosage Form 1998, Churchill Livingstone. M.E. Aulton (Ed.).
46. R.M. Silverstein, Francis X. Webster, Spectometric identification of organic compounds, 6th ed., Authorized reprint by Wiley India of Edition published by John Wiley & Sons. 2010, pp. 136-140.
47. Garekani H.A., Sadeghi F., Badiee A., Mostafa S.A., Rajabi-Siahboomi A.R. Crystal habit modifications of ibuprofen and their physicomechanical characteristics. Drug Development and Industrial Pharmacy 2001, 27:803-809.
48. Staniforth J.N. Powder flow. Pharmaceutics: The Science of Dosage Form 1998, 604. Churchill Livingstone. M.E. Aulton (Ed.).
49. Stanton M., Bak A. Physicochemical properties of pharmaceutical cocrystals: a case study of ten AMG 517 co-crystals. Crystal Growth and Design 2008, 8:3856-3862.
50. S. J. Bethune, Thermodynamic and kinetic parameters that explain crystallization and solubility of pharmaceutical cocrystals, A Ph.D. Dissertation, The University of Michigan, 2009.
51. Yadav A.V., Dabke A.P., Shete A.S. Crystal engineering to improve physicochemical properties of mefloquine hydrochloride. Drug Development and Industrial Pharmacy 2010, 36:1036-1045.